Gaoya Xu
State Key Laboratory Of Drug Research
Shanghai, China
Shanghai, China
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 15 publications
Identification of Novel β-Lactam Derivatives as Proteasome Inhibitors for Antitumor Therapy.
Journal: Archiv der Pharmazie
Published: March 19, 2025
Palladium-Catalyzed Enantioselective Arylative Dearomatization of Naphthols and Phenols for Constructing Quinazoline-Containing Spirocycles.
Journal: Angewandte Chemie (International ed. in English)
Published: February 10, 2025
Development of novel epoxyketone macrocyclic peptidyl proteasome inhibitors through OPA-mediated one-step cyclization of unprotected peptides.
Journal: Bioorganic chemistry
Published: December 28, 2024
Potent and selective LSD1 inhibitor DC551040 reveals a promising combination therapy for AML with insight into epigenetic dysregulation.
Journal: Signal transduction and targeted therapy
Published: December 24, 2024
Integrative proteogenomic and pharmacological landscape of acute myeloid leukaemia.
Journal: Science bulletin
Published: June 24, 2024
Discovery of 5-trifluoromethyl-2-aminopyrimidine derivatives as potent dual inhibitors of FLT3 and CHK1.
Journal: RSC medicinal chemistry
Published: October 25, 2023
Structure-Activity Relationship Study of Indolin-5-yl-cyclopropanamine Derivatives as Selective Lysine Specific Demethylase 1 (LSD1) Inhibitors.
Journal: Journal of medicinal chemistry
Published: February 24, 2022
Corrigendum to "MicroRNA-21 suppresses PTEN and hSulf-1 expression and promotes hepatocellular carcinoma progression through AKT/ERK pathways" [Cancer Letters 337 (2013) 226-236].
Journal: Cancer letters
Published: January 27, 2020
Corrigendum to "MicroRNA-21 suppresses PTEN and hSulf-1 expression and promotes hepatocellular carcinoma progression through AKT/ERK pathways" [Canc. Lett. 337 (2013) 226-236].
Journal: Cancer letters
Published: January 14, 2020
Last Updated: 09/26/2026